Does high lipoprotein(a) plus elevated apolipoprotein B and remnant lipoproteins raise atherosclerotic risk even when LDL cholesterol is normal?

The clinical assessment of cardiovascular risk is increasingly shifting from a focus on cholesterol mass (LDL-C) to a more comprehensive evaluation of atherogenic particle burden. Evidence confirms that when lipoprotein(a) [Lp(a)] is elevated, the presence of high apolipoprotein B (ApoB) and remnant lipoproteins significantly amplifies atherosclerotic risk, regardless of whether LDL cholesterol levels are within "normal" ranges.

Clinical and synergistic risk

Research consistently demonstrates that Lp(a), ApoB, and remnant lipoproteins are independent, causal risk factors for atherosclerotic cardiovascular disease (ASCVD).

• Independent Contribution: Large-scale meta-analyses of over 27,000 patients show that high Lp(a) increases risk across all achieved LDL-C levels, including those below 70 mg/dL.
• Additive Risk: Multivariable Mendelian randomization (MVMR) indicates that the risk from Lp(a) remains significant even after adjusting for total ApoB and triglycerides. When both Lp(a) and ApoB are elevated, they contribute cumulative damage to the arterial wall.
• Remnant Impact: Remnant cholesterol (cholesterol within VLDL and chylomicron remnants) serves as a potent predictor of major adverse cardiovascular events (MACE). High remnant levels provide prognostic value beyond LDL-C and can identify risk in individuals who otherwise appear to have low lipid profiles.

Mechanistic explanations

The increased risk seen with these markers, even when LDL-C is normal, is driven by the specific biological characteristics of the particles involved:

• Particle Count vs. Mass: LDL-C measures the total amount of cholesterol carried in LDL particles, whereas ApoB measures the total number of all atherogenic particles (LDL, VLDL, and remnants). In many patients, LDL-C may be low, but the total number of particles (ApoB) remains high, a state known as discordance that is associated with higher risk.
• Potency of Lp(a): Lp(a) is essentially an LDL-like particle with an added apolipoprotein(a) protein. It is more atherogenic and pro-thrombotic than standard LDL. Studies suggest that an Lp(a)-associated ApoB particle confers a 1.28 to 1.47 times higher coronary heart disease risk than a standard LDL-associated particle.
• Remnant Entrapment: Like LDL, remnant lipoproteins can become trapped in the arterial intima, but they can be taken up by macrophages more easily without oxidative modification, potentially accelerating foam cell formation and plaque progression.

Bottom line

"Normal" LDL-C levels can be misleading as they do not account for the total atherogenic particle burden. Elevated ApoB and remnant lipoproteins represent a significant source of "residual risk" that further compounds the dangers of high Lp(a), necessitating a more nuanced lipid panel evaluation for accurate risk stratification.